GSK Bought More Shares of Biotech Wave Life Sciences
GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional ...
Yahoo Finance3d
Here's Why GSK (GSK) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence ... Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...
Investing9d
GlaxoSmithKline stock outlook revised as US Arexvy sales fall short - Jefferies
Despite the lowered price target, GSK's financials show some positive indicators ... 8.78 for the last twelve months as of Q2 2024, the stock appears reasonably valued compared to industry ...
moneycontrol.com1mon
Stock Radar: AU SFB, GIC, GSK Pharma, Godfrey Phillips, Exicom, Ecos India Mobility in focus on Wednesday
The floor price has been set at Rs 395 per share. The company has signed a term sheet for the sale of its retail business 24Seven to retail startup New Shop, reports CNBC-TV18 quoting sources The ...
Yahoo Finance3d
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
Price Action: GSK stock is up 7.68% at $40.94 at the last check on Wednesday. Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access ...
Investing9d
GlaxoSmithKline stock outlook revised as US Arexvy sales fall short - Jefferies
adjusted its price target for shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK (LON:GSK)), reducing it to GBP20.00 from a previous GBP21.00. Despite this change, the firm maintained a Buy rating on ...